| Bioactivity | Emicerfont is a corticotropin-releasing factor type 1 (CRF1) receptor antagonist with an IC50 of 66 nM. |
| Target | IC50: 66 nM (CRF1 receptor) |
| Invitro | Emicerfont is a corticotropin-releasing factor type 1 (CRF1) receptor antagonist with an IC50 of 66 nM[1]. |
| In Vivo | At concentration of 10 mg/kg, Emicerfont reduces i.c.v. CRF-induced gerbil forepaw treading and marmoset defensive postures. Emicerfont also reduces rat pup ultrasonic vocalization at concentration of 30 mg/kg[1]. |
| Name | Emicerfont |
| CAS | 786701-13-1 |
| Formula | C22H24N6O2 |
| Molar Mass | 404.46 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
| Reference | [1]. Zorrilla EP, et al. Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 2013 Mar 1;128(3):175-86. |